Background: In chronic liver disorders, a precise Evaluation of hepatic fibrosis is essential from a medical perspective. The glycosylation isomer of Mac-2 binding protein (M2BPGi) is a novel blood marker for liver fibrosis. M2BPGi is able to predict the development and prognosis of hepatocellular carcinoma (HCC) in addition to hepatic fibrosis in individuals with long-term liver diseases, such as persistent hepatitis C virus (HCV). In patients with cirrhosis, M2BPGi can also be utilized to assess liver function and prognosis. The etiology and the presence or lack of treatment affect M2BPGi levels. Consequently, the background and treatment status must be taken into account while establishing the M2BPGi threshold for the diagnosis of hepatic fibrosis and the prediction of the development of HCC.

Aim: to assess the value of the glycosylation isomer of Mac-2 binding protein as a predictor of hepatocellular carcinoma in hepatitis C virus patients.

Conclusion: In the HCV cohort, M2BPGi can be utilized to predict HCC. evaluating M2BPGi as a biomarker for HCC in a wider range of patient populations—including those with severe hepatic fibrosis burdens and a wider range of liver diseases—more research is required.